Atossa Therapeutics, Inc.
ATOS
$1.09
-$0.10-8.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.25% | -14.29% | 18.15% | -16.07% | 38.46% |
| Total Depreciation and Amortization | 0.00% | -20.00% | -71.43% | 33.33% | 33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.86% | 34.37% | 49.90% | 165.44% | -92.29% |
| Change in Net Operating Assets | -68.62% | -74.60% | -190.06% | -98.73% | 50.85% |
| Cash from Operations | -60.21% | -26.84% | -26.57% | -22.33% | -1.48% |
| Capital Expenditure | 100.00% | -50.00% | -- | -900.00% | 76.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -50.00% | -- | -900.00% | 76.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 100.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.71% | -32.62% | 33.91% | 11.18% | 0.98% |